ProBio and GCP ClinPlus Form Strategic Alliance to Accelerate Cell and Gene Therapy Trials in China
核心洞察
ProBio Inc. (搜索) and GCP ClinPlus (搜索) announced a strategic collaboration to accelerate Investigator-Initiated Trials (IITs) in China, addressing operational efficiency and regulatory compliance challenges faced by biopharma sponsors.
The partnership combines ProBio's biologics and cell and gene therapy (搜索) CDMO expertise with GCP ClinPlus (搜索)'s clinical trial execution capabilities across China's hospital network.
The collaboration supports advanced therapeutic modalities including in vivo CAR-T (搜索), gene therapy (搜索), cancer vaccines (搜索), and gene editing therapies (搜索) through an integrated development-to-clinical execution model.
ProBio Inc. (搜索) and GCP ClinPlus (搜索) announced a strategic collaboration designed to accelerate Investigator-Initiated Trials (IITs) in China and provide integrated, end-to-end clinical and development solutions for global biopharma customers. The partnership addresses growing challenges related to operational efficiency, regulatory compliance, and fragmented vendor management that biopharma sponsors frequently encounter in China's clinical research landscape.
Integrated Platform for Advanced Therapeutics
The collaboration unites ProBio Inc. (搜索)'s deep expertise in biologics and cell and gene therapy (搜索) (CGT) CDMO services with GCP ClinPlus (搜索)'s robust capabilities in clinical trial execution and site management across China. The combined offering supports cutting-edge therapeutic modalities, including in vivo CAR-T (搜索), gene therapy, cancer vaccines (搜索), and gene editing therapies (搜索).
This unified service model simplifies clinical execution in China and accelerates study timelines. ProBio Inc. (搜索) contributes extensive experience in early development and translational science, having supported over 40 IIT programs across diverse CGT pipelines. Complementing this, GCP ClinPlus (搜索) brings significant clinical execution expertise, with a track record spanning more than 80 CGT projects and a well-established network of principal investigators across leading public and private hospitals in China.
Streamlined Development-to-Clinical Pathway
The partnership creates tangible value by reducing the disconnect between development and clinical execution. Both companies combine excellence in development, regulatory affairs, and clinical operations, covering project management, clinical monitoring, pharmacovigilance, and biostatistics, to ensure higher-quality and more efficient trial execution.
This coordinated, two-party model offers international biopharma companies a simplified entry point into China's clinical research ecosystem, reducing vendor complexity while accelerating local trial execution. By integrating CMC, non-clinical studies, and clinical operations into one coordinated solution, the collaboration accelerates IIT start-up timelines and enables more efficient engagement with global biotech partners.
"This marks an important step in how we support global innovators entering China," stated Allen Guo, CEO of ProBio. "By bringing development and clinical execution closer together, we can help our clients move Investigator-Initiated Trials forward with greater speed, confidence, and simplicity."
The strategic alliance aims to help bring innovative, potentially life-saving therapies to patients faster, underscoring a shared commitment to advancing therapeutic development and improving patient access to innovative treatments in China.